Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US7101704

Title:Antigen presenting mesenchymal stem cells
Inventors:Mosca, Joseph; Ellicott City, MD, USA
Summary:Described herein is a novel composition comprising an antigen-presenting mesenchymal stem cell of the adipocyte lineage and which expresses at least one co-stimulatory molecule. The mesenchymal stem cell described herein has been modified to have at least one exogenous antigen bound to at least one primary surface molecule such that at least one antigen can initiate an immune response while also expressing at least one co-stimulatory molecule. The antigen is described as preferably being a protein, a polypeptide, a lipid or a glycolipid, with a primary surface molecule of MHC I, MHC II or CD1. Further described is a method by which the mesenchymal stem cell may be contacted with interferon-gamma, and methods by which the state of activation of a T lymphocyte population may be determined. Applications for the treatment and prevention of various diseases are described, utilizing the immune response elicited by the antigen described herein.
Abstract:Disclosed is a mesenchymal stem cell and/or cell of the adipocyte lineage that (i) has been modified to have at least one exogenous antigen bound to at least one primary surface molecule of said cell such that said at least one antigen can initiate an immune response and (ii) also expresses at least one co-stimulatory molecule. The antigen is preferably a protein, polypeptide, lipid or glycolipid. The primary surface molecule is MHC I, MHC II or CD1. Also disclosed is a method for stimulating presentation of at least one exogenous antigen fragment on a mesenchymal stem cell primary surface molecule by contacting a mesenchymal stem cell that is capable of expressing at least one co-stimulatory molecule with (i) an exogenous antigen or (ii) genetic material that codes for the exogenous antigen which the mesenchymal stem cell processes into at least one antigen fragment. The method can further include contacting the mesenchymal stem cell with interferon-γ. Also disclosed are a method for determining the state of activation of a T lymphocyte population and a method for the treatment or prevention of a disease in an animal.
US Patent Website:Click Here for Full Text of Patent
Title Number:US7101704
Application Number:US2000000638358
Date Filed:15/08/2000
Date Published:05/09/2006
Assignee:Osiris Therapeutics, Inc., Baltimore, MD, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/13/2021